Full dose, half dose, or discontinuation of etanercept biosimilar in early axial spondyloarthritis patients: a real-world study in China

INTRODUCTION: To investigate the effect of dose maintenance, reduction, or discontinuation of the etanercept biosimilar Yisaipu (YSP) on early axial spondyloarthritis (axSpA) patients in remission with YSP 50 mg once weekly (QW). MATERIAL AND METHODS: Patients were enrolled in three groups: full dos...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Arch Med Sci
Prif Awduron: Li, Kun-Peng, Jin, Jing-Yu, Yang, Jin-Shui, Li, Yan, Zhao, Wei, Luo, Gui, Zhu, Jian, Zhang, Jiang-Lin, Huang, Feng
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Termedia Publishing House 2018
Pynciau:
Clinical Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6524190/
https://ncbi.nlm.nih.gov/pubmed/31110537
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/aoms.2018.76141
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg